Morgan Stanley Enlivex Therapeutics Ltd. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Morgan Stanley holds 72,120 shares of ENLV stock, worth $95,198. This represents 0.0% of its overall portfolio holdings.

Number of Shares

72,120

Previous 44,460 62.21%

Holding current value

$95,198

Previous $120,000 127.5%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.54 - $4.3 $70,256 - $118,938	27,660 Added 62.21%	72,120 $273,000
Q4 2023 Feb 13, 2024	BUY	$1.29 - $2.92 $392 - $887	304 Added 0.69%	44,460 $120,000
Q3 2023 Nov 15, 2023	BUY	$1.46 - $2.97 $445 - $905	305 Added 0.7%	44,156 $69,000
Q2 2023 Aug 14, 2023	BUY	$2.51 - $3.71 $9,266 - $13,697	3,692 Added 9.19%	43,851 $115,000
Q1 2023 May 15, 2023	SELL	$3.41 - $4.55 $1,933 - $2,579	-567 Reduced 1.39%	40,159 $146,000

Q4 2022 Feb 14, 2023	SELL	$3.74 - $4.81 $14,174 - $18,229	-3,790 Reduced 8.51%	40,726 $160,000
Q3 2022 Nov 14, 2022	BUY	$4.11 - $5.87 $48,461 - $69,213	11,791 Added 36.03%	44,516 $189,000
Q2 2022 Oct 27, 2022	BUY	$3.81 - $8.64 $42,481 - $96,336	11,150 Added 51.68%	32,725 $148,000
Q2 2022 Aug 15, 2022	BUY	$3.81 - $8.64 $42,481 - $96,336	11,150 Added 51.68%	32,725 $148,000
Q1 2022 Oct 27, 2022	SELL	$4.92 - $6.66 $54,858 - $74,259	-11,150 Reduced 34.07%	21,575 $121,000
Q1 2022 May 13, 2022	BUY	$4.92 - $6.66 $21,716 - $29,397	4,414 Added 25.72%	21,575 $121,000
Q4 2021 Feb 14, 2022	SELL	$5.81 - $9.73 $8,029 - $13,446	-1,382 Reduced 7.45%	17,161 $107,000
Q3 2021 Nov 15, 2021	BUY	$7.43 - $13.86 $137,774 - $257,005	18,543 New	18,543 $183,000

Others Institutions Holding ENLV

# of Institutions

Shares Held

324K

Call Options Held

22.8K

Put Options Held

29.1K

View Full List

About Enlivex Therapeutics Ltd.

Ticker ENLV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,403,200
Market Cap $24.3M
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...

More about ENLV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account